For: | Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol 2022; 14(6): 1053-1073 [PMID: 35978668 DOI: 10.4254/wjh.v14.i6.1053] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v14/i6/1053.htm |
Number | Citing Articles |
1 |
Palak K. Parikh, Nisha H. Parikh, B. Mahalakshmi, Ketan M. Ranch, Sai HS. Boddu, R Jayachandra Babu, Amit K. Tiwari. Developments in Small Molecule Antiviral Drugs against Hepatitis B and C Viruses: FDA Approved Therapies and New Drugs in Clinical Trials. Arabian Journal of Chemistry 2023; : 105013 doi: 10.1016/j.arabjc.2023.105013
|
2 |
Hala L. Fayed, Sohair M. Abd El Ghany, Abeer M. Nasser, Naglaa A. El-gendy. Effectiveness of direct-acting antiviral (DAA) agents on hepatitis C virus-related mixed cryoglobulinemia syndrome: One-year follow-up. The Egyptian Rheumatologist 2023; 45(2): 139 doi: 10.1016/j.ejr.2022.12.004
|